A Phase I, Single-Center, Randomized, Single-Blind, Placebo-Controlled, Single-Dose, Dose-Escalation Study to Evaluate the Tolerability, Safety, and Pharmacokinetics of an Intravenous Infusion of INO-4885 Administered to Healthy Adult Male Volunteers Part 3
Latest Information Update: 30 Jun 2016
At a glance
- Drugs INO 4885 (Primary)
- Indications Kidney disorders
- Focus Adverse reactions
- Sponsors Inotek Pharmaceuticals
- 30 Jun 2016 New trial record